




Endeavour biotech startup: How building or joining a startup compares to working for a large company



Dr. Uli Ohmayer



Uli Ohmayer received his Diploma in Biochemistry from the University of Regensburg in 2010 where he continued with a PhD thesis focusing on RNP biology in Herbert Tschochner's Lab at the Chair of Biochemistry III. In 2014 he started a Post-Doc at the proteomics Core Facility of the Helmholtz Center Munich where he gained hands-on experiences in state-of-the art mass spectrometry-based proteomics. In 2017 he switched to industry by starting a research scientist position at Polyquant GmbH, a small biotech company located in Bad Abbach before he joined the Munich site of Evotec SE, a globally operating CRO in 2018. At Evotec he was involved in a proteomics collaboration with a large cap biotech company to support early-stage drug discovery programs in the field of targeted protein degradation where he was responsible for implementing a scalable proteomics screening approach. In 2022 he left Evotec and co-founded NEOsphere Biotechnologies GmbH, a privately funded Munich-based biotech startup company where he is heading the mass spectrometry department.

Uli will share his experiences and give insights into how working for a large, globally operating company compares to an endeavour such as co-founding and start a biotech startup. He will also review some of his career decisions and try to give advice for attending (PhD) students.

Monday, 13.01.2025, 17:00 h
DE_2.121